Andrew von Eschenbach news from FierceBiotech
News
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
ALSO NOTED: MAP touts IIa data; Isis pockets $2M milestone;and much more...
> A surge of hopeful research reports on the potential of stem cells has helped fatten profits at Cryo-Save. The company says its stem cell storage work jumped 41 percent last year. Demand is Read more...
Eschenbach offers 'Andy's Take' on FDA issues
Eschenbach offers 'Andy's Take' on FDA issues The ever-growing blogosphere has a new voice--none other than FDA commissioner Andrew von Eschenbach. At Read more...
ALSO NOTED: Rumor Mill: AstraZeneca a possible Shire suitor; Cardiome baits hook for partners; Vertex shares keep sliding; and
> Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. Read more...
ALSO NOTED: Manhattan Pharma closes JV deal; Abbott, Genentech, WEHI in cancer collaboration; and much more...
> Manhattan Pharmaceuticals has closed on its joint venture agreement with Nordic Biotech Venture Fund II K/S to develop and commercialize Hedrin for head lice for the North American market. Read more...
House passes PDUFA: bill heads to Senate
The U.S. House of Representatives has passed a bill to renew the Prescription Drug User Fee Act (PDUFA), positioning it to be passed by the Senate and signed by the President before the Friday Read more...
ALSO NOTED: FDA approves MedPointe's SOMA; EntreMed secures $20M loan; and much more...
> The FDA has approved MedPointe's SOMA (carisoprodol) 250 mg as a new recommended dose for the relief of discomfort associated with acute, painful musculoskeletal conditions, such as backache. Read more...
FDA to address nanotechnology standards
Nanotechnology has enormous potential to revolutionize the drug, medical device, cosmetic and food industries, but according to a new report, the FDA lacks a standard regulatory procedure for Read more...
FDA offers safety reforms to skeptical lawmakers
The FDA has outlined new steps aimed at improving the way new drugs are monitored following approval. In response to a Read more...
Senate confirms von Eschenbach as chief of FDA
Andrew von Eschenbach gained the overwhelming support of the Senate in his long-delayed bid to become chief of the FDA. Senators supported his nomination by a vote of 80 to 11. Among the small band of opponents were several Republicans, including Senator Charles Grassley, who has been steaming over what he sees as a lack of cooperation at the agency in his …
Read more...Get more Andrew von Eschenbach coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

